Cargando…

Real-world experience with 240 mg of galcanezumab for the preventive treatment of cluster headache

BACKGROUND: Galcanezumab of 300 mg monthly is the FDA approved preventive medication for cluster headache (CH) during the cluster period. Compared to the 120 mg galcanezumab syringe for the treatment of migraines, the 100 mg syringe for CH has globally not been as widely available. The aim of our st...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mo, Heejung, Kim, Byung-Kun, Moon, Heui-Soo, Cho, Soo-Jin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Milan 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9547445/ https://www.ncbi.nlm.nih.gov/pubmed/36209047 http://dx.doi.org/10.1186/s10194-022-01505-w

Ejemplares similares

Preventive therapy with galcanezumab for two consecutive cluster bouts in patients with episodic cluster headache: an observational multicenter study
por: Hong, Yooha, et al.
Publicado: (2023)

Reducing Episodic Cluster Headaches: Focus on Galcanezumab
por: Pellesi, Lanfranco, et al.
Publicado: (2020)

Tolerability and safety of galcanezumab in patients with chronic cluster headache with up to 15 months of galcanezumab treatment
por: Láinez, Miguel J. A., et al.
Publicado: (2021)

Oxygen Therapy in Cluster Headache, Migraine, and Other Headache Disorders
por: Mo, Heejung, et al.
Publicado: (2022)

Clinical Features of Cluster Headache Patients in Korea
por: Moon, Heui-Soo, et al.
Publicado: (2017)

Efficacy and Safety of Galcanezumab as a Preventive Treatment for Episodic Migraine in South Korean Patients: A Post-Hoc Analysis of a Phase 3 Clinical Trial
por: Kim, Byung-Kun, et al.
Publicado: (2023)

Development and Validation of the Cluster Headache Screening Questionnaire
por: Chung, Pil-Wook, et al.
Publicado: (2019)

Smoking History and Clinical Features of Cluster Headache: Results from the Korean Cluster Headache Registry
por: Chung, Pil-Wook, et al.
Publicado: (2021)

Galcanezumab for the treatment of chronic migraine and medication overuse headache: Real‐world clinical evidence in a severely impaired patient population
por: Guerzoni, Simona, et al.
Publicado: (2023)

Fremanezumab and Non-High-Dose Galcanezumab for Comorbid Cluster Headache in Patients with Migraine: Three Cases
por: Kashiwagi, Kenta, et al.
Publicado: (2023)

S240. DETERMINANT FACTORS OF REAL-WORLD FUNCTIONING IN SCHIZOPHRENIA
por: González-Blanco, Leticia, et al.
Publicado: (2018)

Diagnostic Delay and Its Predictors in Cluster Headache
por: Kim, Byung-Su, et al.
Publicado: (2022)

Chronic Daily Headache and Medication Overuse Headache in First-Visit Headache Patients in Korea: A Multicenter Clinic-Based Study
por: Cha, Myoung-Jin, et al.
Publicado: (2016)

Real-world evidence of galcanezumab for migraine treatment in Japan: a retrospective analysis
por: Takizawa, Tsubasa, et al.
Publicado: (2022)

Predictors of galcanezumab response in a real-world study of Korean patients with migraine
por: Kim, Seung Ae, et al.
Publicado: (2023)

Differences in Characteristics and Comorbidity of Cluster Headache According to the Presence of Migraine
por: Song, Tae-Jin, et al.
Publicado: (2019)

The impact of remission and coexisting migraine on anxiety and depression in cluster headache
por: Kim, Byung-Su, et al.
Publicado: (2020)

Real-life experiences with galcanezumab and predictors for treatment response in Turkey
por: Yalinay Dikmen, Pınar, et al.
Publicado: (2023)

Different doses of galcanezumab versus placebo in patients with migraine and cluster headache: a meta-analysis of randomized controlled trials
por: Yang, Yanbo, et al.
Publicado: (2020)

Clinical features of chronic cluster headache based on the third edition of the International Classification of Headache Disorders: A prospective multicentre study
por: Cho, Soo-Jin, et al.
Publicado: (2019)

Galcanezumab for migraine
Publicado: (2020)

Clinical Features of Probable Cluster Headache: A Prospective, Cross-Sectional Multicenter Study
por: Sohn, Jong-Hee, et al.
Publicado: (2018)

Characteristics of Elderly-Onset (≥65 years) Headache Diagnosed Using the International Classification of Headache Disorders, Third Edition Beta Version
por: Song, Tae-Jin, et al.
Publicado: (2016)

Clinical factors influencing the impact of cluster headache from a prospective multicenter study
por: Sohn, Jong-Hee, et al.
Publicado: (2020)

Impact of cluster headache on employment status and job burden: a prospective cross-sectional multicenter study
por: Choi, Yun-Ju, et al.
Publicado: (2018)

Associated Factors and Clinical Implication of Cutaneous Allodynia in Patients with Cluster Headache: A Prospective Multicentre Study
por: Kim, Byung-Su, et al.
Publicado: (2019)

One-Time Use of Galcanezumab or Fremanezumab for Migraine Prevention
por: Katsuki, Masahito, et al.
Publicado: (2023)

Factors Associated with Incidental Neuroimaging Abnormalities in New Primary Headache Patients
por: Kim, Byung-Su, et al.
Publicado: (2020)

Phase 3 randomized, placebo-controlled study of galcanezumab in patients with chronic cluster headache: Results from 3-month double-blind treatment
por: Dodick, David W, et al.
Publicado: (2020)

Analyses of Nivolumab Exposure and Clinical Safety Between 3-mg/kg Dosing and 240-mg Flat Dosing in Asian Patients with Advanced Renal Cell Carcinoma in the Real-World Clinical Setting
por: Kato, Renpei, et al.
Publicado: (2020)

Clinical features of cluster headache without cranial autonomic symptoms: results from a prospective multicentre study
por: Chu, Min Kyung, et al.
Publicado: (2021)

Galcanezumab effect on “whole pain burden” and multidimensional outcomes in migraine patients with previous unsuccessful treatments: a real-world experience
por: Silvestro, Marcello, et al.
Publicado: (2022)

Comprehensive Application of the International Classification of Headache Disorders Third Edition, Beta Version
por: Kim, Byung-Kun, et al.
Publicado: (2016)

Health Tract, No. 240: Cholera Prevented
Publicado: (1866)

The Role of Galcanezumab in Migraine Prevention: Existing Data and Future Directions
por: Gklinos, Panagiotis, et al.
Publicado: (2021)

Associations of Elderly Onset Headache With Occurrence of Poor Functional Outcome, Cardiovascular Disease, and Cognitive Dysfunction During Long-term Follow-up
por: Cho, Soo-Jin, et al.
Publicado: (2018)

Treatment Outcomes in Patients Treated With Galcanezumab vs Placebo: Post Hoc Analyses From a Phase 3 Randomized Study in Patients With Episodic Cluster Headache
por: Kudrow, David, et al.
Publicado: (2020)

Short-term diagnostic stability of probable headache disorders based on the International Classification of Headache Disorders, 3rd edition beta version, in first-visit patients: a multicenter follow-up study
por: Kim, Byung-Su, et al.
Publicado: (2016)

Efficacy and Safety of Galcanezumab for the Preventive Treatment of Migraine: A Narrative Review
por: Martin, Vincent, et al.
Publicado: (2020)

Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination
por: Raffaelli, Bianca, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_hs6tc5mc6r8onpksjfjuq30m4j